Skip to content

Tobramycin 0.3% vs. Dual Therapy with Fortified Cefazolin and Ciprofloxacin in Bacterial Keratitis

Evaluating the Effectiveness of Tobramycin 0.3 percent vs. Dual Therapy with Fortified Cefazolin and Ciprofloxacin in Bacterial Keratitis of moderate severity - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086457
Enrollment
120
Registered
2025-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H160- Corneal ulcer

Interventions

Intervention1: Antibiotic Therapy: Cephazoline and Ciprofloxin combination vs Tobramycin. Follow-up visits: 3 days, 1 week, 2 weeks, 4 weeks, 6 weeks, 2 months, and 3 months. Control Intervention1: An

Sponsors

L V Prasad Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Microbiologically confirmed bacterial keratitis smear or smear negative cases where the the fungus has been ruled out by microscopic examination. 2.No prior study medication use exceeding six times per day for more than 10 days. 3.Corneal infiltrate size 4 6 mm, with stromal involvement not exceeding two-thirds of corneal thickness. 4.Vision in the other eye better than 20/200. 5.Willingness to participate in the study. 6.Non-pregnant individuals. 7.Systemically stable patients. 8.Willingness for admission or regular follow-up.

Exclusion criteria

Exclusion criteria: 1.Mixed infection 2.Participant not willing to participate 3.Having Advanced form of infection 4.Limbal involvement 5.Scleral involvement 6.Posterior chamber involvement

Design outcomes

Primary

MeasureTime frame
1.Number of cases achieving medical cure. 2.Incidence of corneal perforations. 3.Number of patients requiring urgent TPK. Timepoint: Follow-up visits: 3 days, 1 week, 2 weeks, 4 weeks, 6 weeks, 2 months, and 3 months.

Secondary

MeasureTime frame
Best spectacle-corrected visual acuity (BSCVA) at 3 months.Timepoint: 3 months

Countries

India

Contacts

Public ContactDrBhupesh Bagga

L V Prasad Eye Institute

bhupesh@lvpei.org9618276424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026